Business Card for Mary Tou Merluzeau:

Director, Bioanalytical Development
Bothell, WA area

Mail: 21823 30th Drive Southeast
Bothell, WA 98021

Tel: (425) 527-4000

Last updated on 2017-05-29

About Mary Tou Merluzeau:

Mary Tou Merluzeau works as an Director, Bioanalytical Development for Seattle Genetics at Bothell, WA. The company's webpage is For email, phone number and executive profiles for Director, Bioanalytical Development and other executives of Seattle Genetics at Bothell, WA, check Seattle Genetics at Not the Mary Tou Merluzeau you are looking for? Do a quick search in our website and find other people named Mary Tou Merluzeau.
Mary Tou Merluzeau's Work History:
No information available..

Mary Tou Merluzeau's Education:
No information available..

Mary Tou Merluzeau's Co-workers:
As of June 20, 2019, Mary Tou Merluzeau has 54 co-workers under the company name Seattle Genetics at

About Seattle Genetics:

Seattle Genetics, Inc. (Seattle Genetics), is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS or brentuximab vedotin is approved by United States Food and Drug Administration (FDA) in two indications: the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT), or ASCT, or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and the treatment of patients with systemic anaplastic large cell lymphoma (ALCL), after failure of at least one prior multi-agent chemotherapy regimen. ADCETRIS is an antibody-drug conjugate, or ADC, comprising an anti-CD30 monoclonal antibody attached by a protea...... (Source: SEC reports)

Company News:
No company news available.

People in the same industry: